Neurosense Therapeutics Ltd (NRSN)

$0.92 -0.01 (-1.06%)
Market Cap 12.58M
Revenue (ttm) 0.00
Net Income (ttm) -10.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 143,400
Avg Vol 329,876
Day's Range N/A - N/A
Shares Out 13.67M
Stochastic %K 42%
Beta 1.62
Analysts Sell
Price Target $10.17

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
forza_juve
forza_juve Feb. 4 at 1:20 AM
$NRSN Why fund a phase 3 trial when you can buy them out cheap (say 50-100mil). Then you do your own phase 3 trial. You control everything (rather than being reliant on NRSN). You probably spend even less money since you are doing the trials yourself. Not only that but if drugs are successful, you keep 100% of the profits (no royalties) Who is “you”??? A big pharma with big pockets. Would this make more sense than funding a phase 3 only??
0 · Reply
Robertsylvan
Robertsylvan Feb. 4 at 12:42 AM
$NRSN Chat GBT says Biogen is best partner candidate for NRSN: Most likely “best match” partner: Biogen Why they fit best (pure strategic + practical match, not a prediction/guarantee): • ALS + AD overlap: They’re one of the few neuro leaders with serious stakes across both diseases (and the trial ops muscle to match). • They know how to run hard neuro Phase 3s: global sites, endpoints, regulators, reimbursement narratives. • Portfolio logic: PrimeC’s “multi-mechanism oral therapy” story complements the biologics-heavy neuro world, and it’s plausible as an add-on / combination concept if signals hold up. If you’re asking “who could most realistically take something like this through Phase 3 and beyond,” Biogen is the cleanest fit.
1 · Reply
Robertsylvan
Robertsylvan Feb. 4 at 12:26 AM
$NRSN we know Alon was in Boston this past week. Take your pick of the big Pharma prospects for him in that area! Big Pharma HQs in the Boston Area • Pfizer 👉 Global HQ: New York 👉 Major R&D / innovation HQ: Cambridge, MA (huge footprint, many execs based there) • Biogen 👉 Headquarters: Cambridge, MA 👉 One of the original Boston biotech giants (neurology focus) • Moderna 👉 Headquarters: Cambridge, MA 👉 mRNA pioneer; global name after COVID • Takeda Pharmaceutical Company 👉 Global HQ: Tokyo 👉 US HQ: Cambridge, MA (post-Shire acquisition) • Vertex Pharmaceuticals 👉 Headquarters: Boston, MA (Seaport) 👉 One of the most successful biotech companies ever (CF franchise)
0 · Reply
Losingit1
Losingit1 Feb. 4 at 12:24 AM
$NRSN Phase 2 complet with good result. Thumbs up for phase 3 from FDA. Lets go!!!
0 · Reply
Robertsylvan
Robertsylvan Feb. 3 at 11:43 PM
$NRSN chat GPT’s answer to question “will NRSN hit $10?”
0 · Reply
mmtiddy
mmtiddy Feb. 3 at 8:52 PM
$NRSN I would like to mention as well, LLMs are trained on articles and forums. If you search up $NRSN there is barely anyone talking about this stock I think only 2 price targets were given last year, and those price targets were based off the ALS & AD markets as a whole and giving a proportion to $NRSN - many big biopharma companies failed to come even close to a solution on ALS & AD, that’s why the PTs are so high I just find it strange, why would an AI mention a stock that is barely discussed about, especially with the sentiment most current holders have
0 · Reply
mmtiddy
mmtiddy Feb. 3 at 8:43 PM
$NRSN Look, I am not saying it is true, but I got the same response from ChatGPT 1 year ago, and look what has happened. I am not saying this company did this, but certain companies have paid for ”ghost advertising” on LLMs to promote their products, I find it wild that from all the biopharma pennystocks out there, the LLM treats $NRSN like a king when it comes to recommendations but fails to mention the core issues with this company Dishonest management, news being delayed for years, the amount of warrants on low prices, lack of actual articles about this company, something fishy is going on to me. This stock has killed me from the inside out, I was promised so many things from management and till now nothing has delivered, nor was I given a proper explanation of why they werent delivered Feel free to chat their Investor Relations for any answers, p.s they never respond
0 · Reply
PennyBLVD
PennyBLVD Feb. 3 at 6:55 PM
$NRSN PS… Now Following You🫵 👍
0 · Reply
PennyBLVD
PennyBLVD Feb. 3 at 6:54 PM
$NRSN WOW!!!👀 That’s Fantastic News!!! Thank you so much for this informative answer!!! 💯🙏
0 · Reply
Stekli27
Stekli27 Feb. 3 at 6:50 PM
$NRSN ALS (PrimeC): • Positive Phase 2b data • Acceptable safety profile • Phase 3 preparation pending funding / partner • This is the core value driver today Alzheimer’s (AD): • Separate program • Safety profile announced in December • Biomarker readout expected (Q1) • Still early-stage and not priced in What NRSN has: • Human clinical data • Clear unmet need in ALS • Active BD discussions What NRSN lacks: • Cash If financing or a partnership is secured, the risk profile changes completely and this is no longer a sub-$1 stock. It all depends on the deal structure, but upside could be very fast and very large (even 500–700%). CEO and team are currently traveling across the US, clearly trying to lock in funding or a partnership to start Phase 3 mid-year. This is a binary setup. And even without cash, analysts still keep Buy ratings with targets around ~$8. Some of us have been waiting here for more than a year already 😉
1 · Reply
Latest News on NRSN
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Jan 21, 2026, 8:30 AM EST - 13 days ago

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Jan 8, 2026, 8:45 AM EST - 26 days ago

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Dec 22, 2025, 9:17 AM EST - 6 weeks ago

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

Dec 4, 2025, 7:30 AM EST - 2 months ago

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

Nov 24, 2025, 9:56 AM EST - 2 months ago

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

NeuroSense to Host Investor Webinar on December 8, 2025

Nov 3, 2025, 9:15 AM EST - 3 months ago

NeuroSense to Host Investor Webinar on December 8, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Oct 6, 2025, 9:00 AM EDT - 4 months ago

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 10, 2025, 2:30 PM EDT - 5 months ago

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Sep 4, 2025, 8:49 AM EDT - 5 months ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Provides Business Update and Progress for the First Half of 2025

Aug 1, 2025, 9:00 AM EDT - 6 months ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Jul 22, 2025, 8:42 AM EDT - 7 months ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025, 3:08 PM EDT - 9 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025, 8:45 AM EDT - 9 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 24, 2025, 9:09 AM EDT - 10 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 9, 2025, 8:30 AM EDT - 10 months ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 7, 2025, 5:14 PM EDT - 10 months ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Apr 4, 2025, 9:10 AM EDT - 10 months ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Mar 17, 2025, 8:30 AM EDT - 11 months ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Jan 6, 2025, 9:00 AM EST - 1 year ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 23, 2024, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 18, 2024, 10:25 AM EST - 1 year ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 11, 2024, 9:25 AM EST - 1 year ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 4, 2024, 8:30 AM EST - 1 year ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Dec 2, 2024, 8:30 AM EST - 1 year ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Nov 21, 2024, 9:20 AM EST - 1 year ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 28, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 24, 2024, 8:30 AM EDT - 1 year ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 15, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 9, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Oct 7, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Sep 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 30, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 7, 2024, 2:00 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 14, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 7, 2024, 8:45 AM EDT - 1 year ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces First Quarter 2024 Business Update

May 2, 2024, 9:19 AM EDT - 1 year ago

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Apr 22, 2024, 8:30 AM EDT - 1 year ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Apr 18, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

Apr 12, 2024, 8:30 AM EDT - 1 year ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

Apr 10, 2024, 7:16 PM EDT - 1 year ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Apr 9, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

forza_juve
forza_juve Feb. 4 at 1:20 AM
$NRSN Why fund a phase 3 trial when you can buy them out cheap (say 50-100mil). Then you do your own phase 3 trial. You control everything (rather than being reliant on NRSN). You probably spend even less money since you are doing the trials yourself. Not only that but if drugs are successful, you keep 100% of the profits (no royalties) Who is “you”??? A big pharma with big pockets. Would this make more sense than funding a phase 3 only??
0 · Reply
Robertsylvan
Robertsylvan Feb. 4 at 12:42 AM
$NRSN Chat GBT says Biogen is best partner candidate for NRSN: Most likely “best match” partner: Biogen Why they fit best (pure strategic + practical match, not a prediction/guarantee): • ALS + AD overlap: They’re one of the few neuro leaders with serious stakes across both diseases (and the trial ops muscle to match). • They know how to run hard neuro Phase 3s: global sites, endpoints, regulators, reimbursement narratives. • Portfolio logic: PrimeC’s “multi-mechanism oral therapy” story complements the biologics-heavy neuro world, and it’s plausible as an add-on / combination concept if signals hold up. If you’re asking “who could most realistically take something like this through Phase 3 and beyond,” Biogen is the cleanest fit.
1 · Reply
Robertsylvan
Robertsylvan Feb. 4 at 12:26 AM
$NRSN we know Alon was in Boston this past week. Take your pick of the big Pharma prospects for him in that area! Big Pharma HQs in the Boston Area • Pfizer 👉 Global HQ: New York 👉 Major R&D / innovation HQ: Cambridge, MA (huge footprint, many execs based there) • Biogen 👉 Headquarters: Cambridge, MA 👉 One of the original Boston biotech giants (neurology focus) • Moderna 👉 Headquarters: Cambridge, MA 👉 mRNA pioneer; global name after COVID • Takeda Pharmaceutical Company 👉 Global HQ: Tokyo 👉 US HQ: Cambridge, MA (post-Shire acquisition) • Vertex Pharmaceuticals 👉 Headquarters: Boston, MA (Seaport) 👉 One of the most successful biotech companies ever (CF franchise)
0 · Reply
Losingit1
Losingit1 Feb. 4 at 12:24 AM
$NRSN Phase 2 complet with good result. Thumbs up for phase 3 from FDA. Lets go!!!
0 · Reply
Robertsylvan
Robertsylvan Feb. 3 at 11:43 PM
$NRSN chat GPT’s answer to question “will NRSN hit $10?”
0 · Reply
mmtiddy
mmtiddy Feb. 3 at 8:52 PM
$NRSN I would like to mention as well, LLMs are trained on articles and forums. If you search up $NRSN there is barely anyone talking about this stock I think only 2 price targets were given last year, and those price targets were based off the ALS & AD markets as a whole and giving a proportion to $NRSN - many big biopharma companies failed to come even close to a solution on ALS & AD, that’s why the PTs are so high I just find it strange, why would an AI mention a stock that is barely discussed about, especially with the sentiment most current holders have
0 · Reply
mmtiddy
mmtiddy Feb. 3 at 8:43 PM
$NRSN Look, I am not saying it is true, but I got the same response from ChatGPT 1 year ago, and look what has happened. I am not saying this company did this, but certain companies have paid for ”ghost advertising” on LLMs to promote their products, I find it wild that from all the biopharma pennystocks out there, the LLM treats $NRSN like a king when it comes to recommendations but fails to mention the core issues with this company Dishonest management, news being delayed for years, the amount of warrants on low prices, lack of actual articles about this company, something fishy is going on to me. This stock has killed me from the inside out, I was promised so many things from management and till now nothing has delivered, nor was I given a proper explanation of why they werent delivered Feel free to chat their Investor Relations for any answers, p.s they never respond
0 · Reply
PennyBLVD
PennyBLVD Feb. 3 at 6:55 PM
$NRSN PS… Now Following You🫵 👍
0 · Reply
PennyBLVD
PennyBLVD Feb. 3 at 6:54 PM
$NRSN WOW!!!👀 That’s Fantastic News!!! Thank you so much for this informative answer!!! 💯🙏
0 · Reply
Stekli27
Stekli27 Feb. 3 at 6:50 PM
$NRSN ALS (PrimeC): • Positive Phase 2b data • Acceptable safety profile • Phase 3 preparation pending funding / partner • This is the core value driver today Alzheimer’s (AD): • Separate program • Safety profile announced in December • Biomarker readout expected (Q1) • Still early-stage and not priced in What NRSN has: • Human clinical data • Clear unmet need in ALS • Active BD discussions What NRSN lacks: • Cash If financing or a partnership is secured, the risk profile changes completely and this is no longer a sub-$1 stock. It all depends on the deal structure, but upside could be very fast and very large (even 500–700%). CEO and team are currently traveling across the US, clearly trying to lock in funding or a partnership to start Phase 3 mid-year. This is a binary setup. And even without cash, analysts still keep Buy ratings with targets around ~$8. Some of us have been waiting here for more than a year already 😉
1 · Reply
PennyBLVD
PennyBLVD Feb. 3 at 5:32 PM
$NRSN can anyone else confirm this? I seriously can’t find anything! When I did my search on grok and google AI I was really hoping to find a stock that was maybe on the barcharts or something popular! I’ve never even heard of this company before today. If anyone else has some insight why grok and google would pick $NRSN it would be greatly appreciated🙏
0 · Reply
PennyBLVD
PennyBLVD Feb. 3 at 4:37 PM
$NRSN LFG🚀🚀🚀
0 · Reply
Speculator2
Speculator2 Feb. 3 at 3:49 PM
$NRSN New horizons?
0 · Reply
PennyBLVD
PennyBLVD Feb. 3 at 3:43 PM
$NRSN Just putting this out there! Hopefully correct🙏 https://x.com/grok/status/2018705342889185545?s=46
1 · Reply
knowthyself
knowthyself Feb. 3 at 3:16 PM
$NRSN looks good to me
0 · Reply
lev57
lev57 Feb. 3 at 7:51 AM
$NRSN If you believe it's close, you'll be in for a surprise and you'll eat your hat. Amazing news. Can give a strong push to the company. To continue its activities. Good luck to the company, to the patients and to all of us.
0 · Reply
mmtiddy
mmtiddy Feb. 3 at 6:37 AM
$NRSN Anything but finalizing a partnership deal huh Alon?
0 · Reply
lev57
lev57 Feb. 3 at 5:14 AM
$NRSN
0 · Reply
lev57
lev57 Feb. 3 at 5:13 AM
Great news! The Senate just passed a bill that increases funding for ALS research! We’re not done yet. The House needs to pass this bill. Let’s show them how important ALS research is. $NRSN
0 · Reply
lev57
lev57 Feb. 2 at 8:37 PM
$NRSN Regarding the CEO, he announced that he would be in Boston. Regarding the lady, I linked to a message that came out from someone close. I see you found her there. Link is solid.
2 · Reply
Stekli27
Stekli27 Feb. 2 at 5:22 PM
$NRSN Do you have some insiders? 😉 Sounds like you’re very well connected to the NRSN travel plans.😉
0 · Reply
Zoofar
Zoofar Feb. 2 at 4:51 PM
$NRSN Bot 2
0 · Reply